|
private:plianttherapeutics
|
7606914
|
Dec 3rd, 2020 12:00AM
|
Pliant Therapeutics
|
2.9K
|
79.00
|
Open
|
Pharmaceuticals
|
Dec 3rd, 2020 12:22PM
|
Dec 3rd, 2020 12:22PM
|
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery.
Pliant’s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
|
Open
|
fibrosis, integrins
|
Open
|
260 Littlefield Ave
|
South San Francisco
|
California
|
US
|
94080
|
|
Pliant Therapeutics
|
|
|
|
private:plianttherapeutics
|
7606914
|
Dec 2nd, 2020 12:00AM
|
Pliant Therapeutics
|
2.9K
|
79.00
|
Open
|
Pharmaceuticals
|
Dec 2nd, 2020 02:44PM
|
Dec 2nd, 2020 02:44PM
|
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery.
Pliant’s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
|
Open
|
fibrosis, integrins
|
Open
|
260 Littlefield Ave
|
South San Francisco
|
California
|
US
|
94080
|
|
Pliant Therapeutics
|
|
|
|
private:plianttherapeutics
|
7606914
|
Dec 1st, 2020 12:00AM
|
Pliant Therapeutics
|
2.9K
|
79.00
|
Open
|
Pharmaceuticals
|
Dec 1st, 2020 02:09PM
|
Dec 1st, 2020 02:09PM
|
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery.
Pliant’s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
|
Open
|
fibrosis, integrins
|
Open
|
260 Littlefield Ave
|
South San Francisco
|
California
|
US
|
94080
|
|
Pliant Therapeutics
|
|
|
|
private:plianttherapeutics
|
7606914
|
Nov 30th, 2020 12:00AM
|
Pliant Therapeutics
|
2.9K
|
79.00
|
Open
|
Pharmaceuticals
|
Nov 29th, 2020 08:12PM
|
Nov 30th, 2020 03:00PM
|
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery.
Pliant’s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
|
Open
|
fibrosis, integrins
|
Open
|
260 Littlefield Ave
|
South San Francisco
|
California
|
US
|
94080
|
|
Pliant Therapeutics
|
|
|
|
private:plianttherapeutics
|
7606914
|
Nov 28th, 2020 12:00AM
|
Pliant Therapeutics
|
2.9K
|
79.00
|
Open
|
Pharmaceuticals
|
Nov 28th, 2020 03:48PM
|
Nov 28th, 2020 03:48PM
|
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery.
Pliant’s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
|
Open
|
fibrosis, integrins
|
Open
|
260 Littlefield Ave
|
South San Francisco
|
California
|
US
|
94080
|
|
Pliant Therapeutics
|
|
|
|
private:plianttherapeutics
|
7606914
|
Nov 27th, 2020 12:00AM
|
Pliant Therapeutics
|
2.9K
|
79.00
|
Open
|
Pharmaceuticals
|
Nov 27th, 2020 12:13PM
|
Nov 27th, 2020 12:13PM
|
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery.
Pliant’s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
|
Open
|
fibrosis, integrins
|
Open
|
260 Littlefield Ave
|
South San Francisco
|
California
|
US
|
94080
|
|
Pliant Therapeutics
|
|
|
|
private:plianttherapeutics
|
7606914
|
Nov 26th, 2020 12:00AM
|
Pliant Therapeutics
|
2.9K
|
79.00
|
Open
|
Pharmaceuticals
|
Nov 26th, 2020 01:12PM
|
Nov 26th, 2020 01:12PM
|
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery.
Pliant’s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
|
Open
|
fibrosis, integrins
|
Open
|
260 Littlefield Ave
|
South San Francisco
|
California
|
US
|
94080
|
|
Pliant Therapeutics
|
|
|
|
private:plianttherapeutics
|
7606914
|
Nov 25th, 2020 12:00AM
|
Pliant Therapeutics
|
2.9K
|
79.00
|
Open
|
Pharmaceuticals
|
Nov 25th, 2020 06:51PM
|
Nov 25th, 2020 06:51PM
|
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery.
Pliant’s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
|
Open
|
fibrosis, integrins
|
Open
|
260 Littlefield Ave
|
South San Francisco
|
California
|
US
|
94080
|
|
Pliant Therapeutics
|
|
|
|
private:plianttherapeutics
|
7606914
|
Nov 24th, 2020 12:00AM
|
Pliant Therapeutics
|
2.9K
|
79.00
|
Open
|
Pharmaceuticals
|
Nov 24th, 2020 02:10PM
|
Nov 24th, 2020 02:10PM
|
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery.
Pliant’s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
|
Open
|
fibrosis, integrins
|
Open
|
260 Littlefield Ave
|
South San Francisco
|
California
|
US
|
94080
|
|
Pliant Therapeutics
|
|
|
|
private:plianttherapeutics
|
7606914
|
Nov 23rd, 2020 12:00AM
|
Pliant Therapeutics
|
2.9K
|
79.00
|
Open
|
Pharmaceuticals
|
Nov 23rd, 2020 04:10PM
|
Nov 23rd, 2020 04:10PM
|
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery.
Pliant’s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
|
Open
|
fibrosis, integrins
|
Open
|
260 Littlefield Ave
|
South San Francisco
|
California
|
US
|
94080
|
|
Pliant Therapeutics
|
|
|